Clinical Trial Categories
Breast Trials
Trial ID 21455
NCT05296798clinicaltrials.gov ID
USOR ID: 21455
Phase III
Phase III, 2 Arm, Randomized, Open Label, Multicenter, Registrational Study Evaluating The Efficacy And Safety Of Giredestrant In Combination With Phesgo Versus Phesgo (+/- Endocrine Therapy) After Induction Chemotherapy (Phesgo+Taxane) In Patients With Previously Untreated Her2-Positive, Estrogen Receptor Positive Locally Advanced Or Metastatic Breast Cancer
Trial ID 17079 FLEX Registry
NCT03053193clinicaltrials.gov ID
USOR ID: 17079
FLEX: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry
Trial ID 20289 EDP Rockville
NCT04254107clinicaltrials.gov ID
USOR ID: 20289
Phase I
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies
Trial ID 20266
NCT04485013clinicaltrials.gov ID
USOR ID: 20266
Phase Ib
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies
Trial ID BO41932 / TAPISTRY
NCT04589845clinicaltrials.gov ID
Phase II
Trial ID 21501
NCT05065411clinicaltrials.gov ID
USOR ID: 21501
Phase II
ARTEST: A Phase 2 Study to Evaluate the Efficacy and Safety of Enobosarm in Combination with Abemaciclib (Enobosarm Combination Group) compared to Estrogen Blocking Agent (Control Treated Group) for the Second Line Treatment of ER+HER2- Metastatic Breast Cancer in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent plus Palbociclib
Trial ID 21448 STAR
NCT05113966clinicaltrials.gov ID
USOR ID: 21448
Phase II
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting (G1T28-213)
Trial ID 19226
NCT04546009clinicaltrials.gov ID
USOR ID: 19226
Phase III
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Trial ID 20363 SERENA-4
NCT04711252clinicaltrials.gov ID
USOR ID: 20363
Phase III
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Trial ID 20396 DESTINY-09
NCT04784715clinicaltrials.gov ID
USOR ID: 20396
Phase III
DESTINY09: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in First-line HER2-positive Breast Cancer
Trial ID 20326 OVELIA
NCT04906395clinicaltrials.gov ID
USOR ID: 20326
Phase III
OVELIA: A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Trial ID 21462 FLAMINGO-01
NCT05232916clinicaltrials.gov ID
USOR ID: 21462
Phase III
FLAMINGO-01: A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy
Trial ID 22101 EMBER-4
NCT05514054clinicaltrials.gov ID
USOR ID: 22101
Phase III
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Trial ID 21380
NCT05169567clinicaltrials.gov ID
USOR ID: 21380
Phase III
postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy